Page 161 - Aet News Today

With the growing complexity of identity management and the challenges posed by market consolidation and digital front door initiatives, it is essential to implement a solution that will effectively manage patient information and prevent duplicates and identity issues.

To address the burden faced by family caregivers across the country, Tomorrow Health CEO Vijay Kedar argues that the U.S. healthcare system should expand its reimbursement for the care they provide. Not only is caregiving physically and emotionally taxing, but it can also cause severe financial strain —many caregivers take time off work and spend their own money to support their loved ones’ care, he explained.

The FDA granted emergency use authorization to an InflaRx antibody drug that treats hospitalized Covid-19 patients. But Pardes Bioscience’s coronavirus journey is ending following the Phase 2 failure of an antiviral that was expected to compete with Pfizer’s Paxlovid.

Oxos Medical recently raised $23 million in Series A funding. The company's handheld X-ray devices are meant to replace C-arms, which are the leading medical imaging technology. The devices are portable are require little training to use, which is key considering the massive dearth of radiologists entering the field.

FDA withdrawal of Makena from the market comes four years after the drug, granted accelerated approval in 2011, failed a post-marketing study to confirm the drug’s benefit. The FDA decision also affects generic versions of the drug.

Pierre Fabre is paying Scorpion Therapeutics $65 million to begin a partnership on clinical development and potential commercialization of two targeted therapies for non-small cell lung cancer. The Scorpion drugs could have safety advantages over approved Johnson & Johnson and Takeda therapies that address the same rare genetic signature.

Zócalo Health, a virtual primary care provider designed for Latino patients, recently forged a collaboration with Mark Cuban's Cost Plus Drugs. Now all Zócalo patients have access to Cost Plus Drugs’ prescriptions, and the provider's community health workers have been trained to help walk patients through the process of obtaining medications through the pharmacy.

Avia CEO Linda Finkel has had many conversations with health systems executives about why their technology initiatives haven’t gone as planned in the past. Based on these experiences, she has noticed four main reasons hospitals don’t see the results for which they were hoping — including not exercising enough scrutiny during the vendor selection process and failure to think about capability at scale.

Preventing drug diversion starts with understanding the signs of a substance use disorder (SUD) in hospital and health system staff workers, those closest to the problem and one of the most affected parties.

The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion. The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests.